Skip to main content
Sign In
 

Publications


Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase

Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson GL, Graham DK.
Oncogene. 2006 Oct 5;25(45):6092-100. Epub 2006 May 1
http://www.ncbi.nlm.nih.gov/sites/entrez/16652142


Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia

Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS
Clin Cancer Res. 2006 May 1;12(9):2662-9.
http://www.ncbi.nlm.nih.gov/sites/entrez/16675557


TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer

Linger RM, Keating AK, Earp HS, Graham DK
Adv Cancer Res. 2008;100:35-83.
http://www.ncbi.nlm.nih.gov/sites/entrez/18620092


Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress

Anwar A, Keating AK, Joung D, Sather S, Kim GK, Sawczyn KK, Brandão L, Henson PM, Graham DK
J Leukoc Biol. 2009 Jul;86(1):73-9. Epub 2009 Apr 22.
http://www.ncbi.nlm.nih.gov/sites/entrez/19386698


Inhibition of Mer and Axl Receptor Tyrosine Kinases Reduces Astrocytoma Cell Growth and Increases Chemosensitivity

Keating AK, Kim GK, Donson A, Ware K, Salzberg DB, Foreman N, Liang X, Graham DK
Molecular Cancer Therapeutics, Manuscript under Revision.


Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia

Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK
Blood. 2009 Sep 24;114(13):2678-87. Epub 2009 Jul 30.
http://www.ncbi.nlm.nih.gov/sites/entrez/19643988


Patents:

Graham, D.K., Linger R., DeRyckere, D., Sather, S., Keating, A.K., Kim, G., Brandao, L.  Methods and compounds for enhancing anti-cancer therapy. Provisional patent filed 7/29/08.


Websites:

Keating, A.K., Linger, R.M.A., Graham, D.K. . MERTK (c-mer proto-oncogene tyrosine kinase). Atlas Genet Cytogenet Oncol Haematol. November 2008 .


Abstracts:

Salzberg DB, Keating, AK, Cao J, Sather S, Hill K, Anwar A, and DK Graham.  2004.  Ectopic expression of Mer receptor tyrosine kinase in childhood T-cell acute lymphoblastic leukemia.  Blood 104:162B. (abstract)

Keating A.K., Sather S., Donson A., Straessle J., Cao J., Foreman N., Graham D.K.  2005. et al: Expression of Mer and Axl receptor tyrosine kinase in pediatric astrocytoma patients. J Clin Oncol 23:127s. (suppl, abstr1555)

Salzberg, D.B., Keating, A.K., Cao, J., Sather, S. and D.K. Graham.  2005. The role of Mer receptor tyrosine kinase in pediatric T cell lymphoblastic leukemia.  PAS 57:494. (abstract)

Keating A.K., Sather S., Donson A., Straessle J., Cao J., Foreman N., Graham D.K.  2006.  The Aberrant Expression of Mer Receptor Tyrosine Kinase in Pediatric Astrocytomas. Pediatr Blood Cancer, 46:692 (abstract).

Linger, R., DeRyckere, D., Brandao, Luis, Sawczyn, K., Keating, A.K., Graham, D.K. 2008.  Synergistic Killing of E2A-PBX1+ B-ALL Cells by Chemotherapeutic Agents and MerTK Inhibition.  Blood 112:982.

Keating A.K., Kim, G.K., Donson A., Foreman N., Graham D.K.  2009.  Inhibition of Mer and Axl tyrosine kinase as a novel therapeutic approach to astrocytic tumors. Proceedings of the AACR. (abstract)